Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 12, 2026Current HIV/AIDS ReportsOpen Access

Systemic Inflammation as a Modulator of FcRn-dependent IgG Pharmacokinetics: Implications for Broadly Neutralising Antibody Efficacy in HIV Prevention

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAndile KhumaloCentre for the AIDS Programme of Research in South AfricaSPSanjali PillayWestern UniversityJMJivanka MohanCentre for the AIDS Programme of Research in South Africa

Discussion

Loading...

Member takes

Implication

Review examines systemic inflammation's role in modulating antibody pharmacokinetics and implications for HIV prevention efficacy in women.

Key Points

  • This review explores how systemic inflammation affects the pharmacokinetics of broadly neutralising antibodies (bNAbs) used for HIV prevention.
  • Review of clinical trial data and therapeutic pharmacokinetic evidence.
  • Analysis of systemic inflammatory biomarkers as predictors of monoclonal antibody clearance.
  • Investigation of the relationship between inflammation and FCGRT gene expression affecting FcRn recycling.
  • Systemic inflammation correlates with faster clearance rates of bNAbs in affected populations.
  • Chronic inflammation downregulates FCGRT gene expression, contributing to decreased bNAb half-life.
  • Standard bNAb dosing may not adequately reflect the inflammatory burden in many individuals, potentially jeopardizing effectiveness.

Cite This Study

Khumalo et al. (2026) studied this question.

synapsesocial.com/papers/6a53315f4f7abc118aded8d8https://doi.org/10.1007/s11904-026-00791-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Association between Galactosylation of Immunoglobulin G and Improvement of Rheumatoid Arthritis during Pregnancy Is Independent of Sialylation2013 · 171 citations
  2. 2Associations between TGF‐ β 1 Levels and Markers of Hemolysis, Inflammation, and Tissue Remodeling in Pediatric Sickle Cell Patients2021 · 15 citations
  3. 3Optimizing Maternal and Fetal Antibody Exposure and Dosing Regimens During Pregnancy Using a Physiologically Based Pharmacokinetic Model2025 · 10 citations
  4. 4Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial2020 · 37 citations
  5. 5Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling2018 · 41 citations